Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Crescendo Biologics closes $70mm Series B

Executive Summary

Crescendo Biologics Ltd. (developing T-cell engagers for cancer) raised $70mm through its Series B round. Lead investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Quan Capital were joined by returning investors Sofinnova Partners, IP Group, EMBL, and Takeda Ventures. Proceeds will help the company advance its lead candidate CB307, a bispecific PSMA-targeted T-cell engager, into clinical trials.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Transgenics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies